Clinical trials
Depressive Disorder, Treatment-Resistant clinical trials
Below are recruiting depressive disorder, treatment-resistant clinical trials, each written for real people, not researchers. We’re tracking 84 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05570344Recruiting
Texting support plus brain stimulation for hard-to-treat depression
This study tests whether adding supportive text messages to brain stimulation (repetitive TMS) helps people with depression that has not improved after at least two antidepressant tries. It may help some people by combining a brain-based treatment with ongoing daily encouragement and support.
Edmonton, AlbertaAges 18 years+ - NCT07422519Recruiting
Virtual reality mindfulness for hard-to-treat depression
This study tests whether using a virtual reality mindfulness program, added to your usual depression care, can help people whose depression hasn't responded to standard treatments.
BarcelonaAges 18–74 - NCT05393622Recruiting
Brain stimulation trial for severe, treatment-resistant depression
This study tests an implanted form of brain stimulation for people with severe depression that has not improved with multiple medication trials. If you qualify, you would have brain scans and surgery planning, then follow a treatment-and-safety plan for several months.
Boston, MassachusettsAges 21–80 - NCT07369102RecruitingPhase 4
Esketamine with or without talk therapy for tough depression
This trial tests if adding a type of talk therapy called integration therapy helps esketamine work better for people with depression that hasn't improved with other treatments. You'll receive esketamine, and some people also get guided sessions to reflect on their experiences.
San JuanAges 21–65 - NCT06784388RecruitingEarly Phase 1
Deep brain stimulation for tough-to-treat depression
This early trial tests a personalized deep brain stimulation (DBS) approach for people with major depression that hasn't improved with at least two different antidepressants. DBS uses small electrodes placed in the brain to adjust mood-related circuits.
Hangzhou, ZhejiangAges 18–70 - NCT07553637RecruitingPhase 2
ALTO-207 for Adults With Hard-to-Treat Depression
This study tests whether a new medication called ALTO-207 can help people with depression that hasn't improved with standard antidepressants. You may qualify if you've tried multiple antidepressants without enough relief and are willing to add this experimental treatment to your current medication.
Birmingham, AlabamaAges 18–75 - NCT02994433RecruitingPhase 1
Testing nitrous oxide for depression brain circuit activity
This early study tests whether nitrous oxide, aimed at specific brain circuits, can change depression-related brain activity. It is mainly for adults with major depression or treatment-resistant depression, and includes brain imaging during the study.
St Louis, MissouriAges 18–65 - NCT07284667RecruitingPhase 2
A new medicine for depression that hasn't improved with other treatments
This trial tests a new medicine called ACP-211 in adults with major depression who have not gotten enough relief from at least two previous antidepressants. The goal is to see if it can help when other treatments have not worked well.
Birmingham, AlabamaAges 18–65 - NCT07543328Recruiting
Light therapy added to antidepressants for depression with body symptoms
This study tests whether a special light treatment applied to the scalp (transcranial photobiomodulation) can help people with depression who aren't getting better with antidepressants alone. The light therapy is added to your current medication to see if it reduces both mood symptoms and physical complaints like pain or fatigue.
TaipeiAges 18–65 - NCT02122562RecruitingPhase 2
Ketamine treatment for depression that hasn’t responded to care
This Phase 2 study tests ketamine for people with major depression that hasn’t improved after at least one antidepressant. It aims to see whether ketamine can reduce depression symptoms during a current depressive episode.
Iowa City, IowaAges 18–55 - NCT07264452Recruiting
Comparing two types of accelerated brain stimulation for tough depression
This study compares two fast types of brain stimulation (called accelerated theta burst stimulation) to see which works better for people whose depression hasn't improved with standard antidepressants. It's designed for people with treatment-resistant depression who are already on a stable antidepressant.
ErzurumAges 18–65 - NCT07226232RecruitingPhase 3
Psilocybin for veterans with treatment-resistant depression
This study tests whether psilocybin (a psychedelic substance) can help veterans with depression that hasn't improved with standard treatments.
Birmingham, AlabamaAges 18–75 - NCT07217223Recruiting
Home-based brain stimulation for treatment-resistant depression
This study tests whether a gentle brain stimulation technique called tDCS can help people with depression that hasn't improved with medication. It can be done at home using a special headset and an internet connection.
San Diego, CaliforniaAges 18–85 - NCT07210112RecruitingPhase 2
Psilocybin and Trazodone for tough-to-treat depression
This trial tests if taking psilocybin (a psychedelic drug) with trazodone (an antidepressant) can help people whose depression hasn't improved with at least two standard antidepressants. If you have treatment-resistant depression, this study might be an option.
ParisAges 18 years+ - NCT07211438RecruitingPhase 2
Psilocybin with Monitors for Treatment-Resistant Depression
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
Toronto, OntarioAges 18–70 - NCT07184619RecruitingPhase 3
Evenamide for hard-to-treat schizophrenia (add-on study)
This trial tests a new medication, evenamide, added to your current antipsychotic treatment. It looks to see if it can help people whose schizophrenia has not responded well to standard therapies.
Los Angeles, CaliforniaAges 18 years+ - NCT07183748RecruitingPhase 2
Psilocybin microdosing plus therapy for hard-to-treat depression
This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.
BeershebaAges 18–65 - NCT07166289Recruiting
Ultrasound treatment for tough depression
This study uses focused ultrasound to stimulate brain circuits in people with treatment-resistant depression. It aims to see if this can help when other treatments haven't worked.
Tulsa, OklahomaAges 18–65 - NCT07088380RecruitingPhase 3
Ketamine combined with ECT for hard-to-treat depression
This trial tests whether adding ketamine to electroconvulsive therapy (ECT) works better than ECT alone for people with depression that hasn't improved with at least two different antidepressants. It may offer a new option for those who have not found relief from standard treatments.
MilanAges 18–70 - NCT07127913Recruiting
Closed-loop brain stimulation for hard-to-treat bipolar depression
This trial tests a closed-loop deep brain stimulation system for people with bipolar II disorder whose depression has not responded to standard treatments. The device sends targeted electrical pulses to the brain based on real-time activity, aiming to reduce depression symptoms.
San Francisco, CaliforniaAges 22–70 - NCT07108257Recruiting
Focused ultrasound for bipolar depression
This trial uses sound waves guided by MRI to target a small brain area. It aims to help people with bipolar depression that hasn't improved with standard treatments.
Toronto, OntarioAges 18–65 - NCT07115628Recruiting
Accelerated TMS for treatment-resistant depression
This trial tests an accelerated form of transcranial magnetic stimulation (TMS) for people with treatment-resistant depression who have been referred for ECT. It aims to offer a non-invasive, less intensive alternative with fewer side effects.
Jette, Brussels CapitalAges 18–70 - NCT07094789Recruiting
Ultrasound therapy for stubborn depression
This trial tests whether a non-invasive ultrasound technique can help people whose depression has not improved with standard treatments. You would receive the ultrasound treatment while having MRI scans to see how your brain changes.
Toronto, OntarioAges 18–65 - NCT07065240RecruitingPhase 2
Study of SPT-300 for major depression with or without anxiety
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
Chino, CaliforniaAges 18–65
Hear when a new Depressive Disorder, Treatment-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for depressive disorder, treatment-resistant?
- Yes. Clin2 currently lists 84 recruiting depressive disorder, treatment-resistant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a depressive disorder, treatment-resistant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a depressive disorder, treatment-resistant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.